From: Altering phosphorylation in cancer through PP2A modifiers
Compound | Cancer Types | Mechanisms | References |
---|---|---|---|
LB-100 | Medulloblastoma | Decreased activation of STAT3 (↑Ser727-p-STAT3) | [144] |
Glioblastoma | Activates Plk-1 and AKT-1, inhibits p53 | [118] | |
Pancreatic cancer | Activates CDC25C/CDK1, inhibits homologous recombination repair (HRR) | [120] | |
Cantharidin | Pancreatic Cancer | G2/M cell cycle arrest, decreased CDK1, and increased p21 | [107] |
Hepatocellular carcinoma | Binds to EphB4, regulating JAK2/STAT3 pathway | [145] | |
Noncantharidin | Colorectal cancer | Activates the CD95 receptor/ligand | [146] |
Okadaic Acid | Lung cancer | Induces apoptosis | |
Calyculin A | Breast cancer | Increases p-Cyclin D1 and initiates its degradation | [147] |
Tautomycin | Medullary thyroid cancer | Inhibition of GSK-3β | [148] |
Tautomycetin | Medullary thyroid cancer | Inhibition of GSK-3β | [148] |
Fostriecin | Leukemia | Binds to Cys269 residue of PP2Ac | [149] |
Small-cell lung carcinoma | Inhibits TopoII without forming a complex with DNA and TopoII | [111] | |
Ovarian cancer | Activates STAT1 | [112] |